Milestone Pharmaceuticals Inc
MIST
Company Profile
Business description
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
Contact
1111 Dr. Frederik-Philips Boulevard
Suite 420
MontrealQCH4M 2X6
CANT: +1 514 336-0444
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
47
Stocks News & Analysis
stocks
3 "buy the dip" candidates with wide moats
Share price pullbacks can present an opportunity to buy high quality companies at attractive prices.
stocks
Undervalued ASX share hampered by delays in foreign expansion
A near monopoly in Australia pushes this company into global markets but progress has been slow.
stocks
Ask the analyst: Why has MinRes fallen so far?
Mineral Resources shares are down almost 50% year to date. Mark Taylor weighs in on some of the reasons why.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,515.20 | 3.70 | -0.04% |
| CAC 40 | 7,226.98 | 199.90 | -2.69% |
| DAX 40 | 19,033.64 | 414.96 | -2.13% |
| Dow JONES (US) | 43,910.98 | 382.15 | -0.86% |
| FTSE 100 | 8,025.77 | 99.42 | -1.22% |
| HKSE | 19,846.88 | 580.05 | -2.84% |
| NASDAQ | 19,281.40 | 17.36 | -0.09% |
| Nikkei 225 | 39,376.09 | 157.23 | -0.40% |
| NZX 50 Index | 12,684.56 | 64.80 | -0.51% |
| S&P 500 | 5,983.99 | 17.36 | -0.29% |
| S&P/ASX 200 | 8,255.60 | 10.60 | -0.13% |
| SSE Composite Index | 3,421.97 | 48.10 | -1.39% |